Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xenon Pharmaceuticals Inc. - Common Shares
(NQ:
XENE
)
38.51
+0.83 (+2.20%)
Delayed Quote
Updated: 1:53 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xenon Pharmaceuticals Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
↗
February 16, 2024
Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset...
Via
Benzinga
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
January 08, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
4 Analysts Have This to Say About Xenon Pharmaceuticals
↗
December 08, 2023
Via
Benzinga
Xenon Pharmaceuticals: Q3 Earnings Insights
↗
November 08, 2023
Via
Benzinga
Earnings Outlook For Xenon Pharmaceuticals
↗
November 07, 2023
Via
Benzinga
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
December 04, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
December 02, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Why Xenon Pharmaceuticals Stock (XENE) Is Seeing Blue Skies Today
↗
November 30, 2023
Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares are trading higher by 7.8% to $36.38 Thursday afternoon. The company announced the pricing of its upsized $300 million public offering of 8,461,542...
Via
Benzinga
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
November 29, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Proposed Public Offering
November 29, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
November 28, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Xenon Pharma's Depression Candidate Shows Positive Signals Of Efficacy, Despite Primary Endpoint Miss: Analyst
↗
November 27, 2023
Monday, Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20...
Via
Benzinga
Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
November 27, 2023
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results.
Via
Benzinga
The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring
↗
November 27, 2023
The company's epilepsy drug also showed promise as a depression treatment.
Via
Investor's Business Daily
What's Going On With Neurology-Focused Xenon Pharmaceuticals' Stock Today?
↗
November 27, 2023
Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of...
Via
Benzinga
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Near the Top of Equities by Percentage Gain on 11/27
November 27, 2023
Via
Investor Brand Network
Ituran Location and Control Posts Q3 Results, Joins Crown Castle, Shopify And Other Big Stocks Moving Higher On Monday
↗
November 27, 2023
U.S. stocks traded mostly lower, with the Dow Jones falling around 50 points on Monday. Shares of Ituran Location and Control Ltd. (NASDAQ: ITRN) gained during Monday’s session after the company...
Via
Benzinga
Topics
Stocks
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
November 27, 2023
Conference call today at 8:30 am ET
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Why Is Neurocrine Biosciences Stock Trading Lower Today?
↗
November 10, 2023
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)
Via
Benzinga
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
November 09, 2023
Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 08, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
November 01, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Earnings Scheduled For November 8, 2023
↗
November 08, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
Via
Benzinga
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
October 09, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 06, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Making Surprising Moves in Tuesday Session
September 26, 2023
Via
Investor Brand Network
Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
September 14, 2023
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
September 12, 2023
Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ET
From
Xenon Pharmaceuticals Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
